MUSK and myasthenia gravis: According to a systematic review of case reports on 169 individuals, the number of patients with MG relapse after treatment was significantly reduced in both the anti-AChR MG (93% before vs. 26% after) and the anti-Muscle-specific kinase (MuSK) MG (100% vs. 14%)47.